Daniel Pearlstein

Prior to joining Canopy Rivers, Daniel was a Principal at Eight Capital and top equity research analyst covering the global cannabis sector. At the time of his departure, he was the longest tenured analyst covering the sector and held the largest coverage universe. He was the only analyst publishing on the industry since inception of the MMPR (now the ACMPR) in April 2014, and is the author of ‘The Value Case For Investing In The Cannabis Sector’. Prior to Eight Capital, Daniel  held an equity research analyst role at a boutique investment bank and established the firm’s healthcare research practice focusing on small cap Canadian clinical- and revenue-stage biotechnology, pharmaceutical, and medical device companies.

Before joining the sell side, he held analyst roles at a North American healthcare venture capital firm, a medical device startup, and a technology transfer incubator analyzing and reviewing opportunities in the life sciences sector. Daniel holds a Bachelor’s Degree in Chemistry from the University of Western Ontario and a Master’s Degree in Management from the University of Toronto.